0001127602-20-001206.txt : 20200106
0001127602-20-001206.hdr.sgml : 20200106
20200106171720
ACCESSION NUMBER: 0001127602-20-001206
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200102
FILED AS OF DATE: 20200106
DATE AS OF CHANGE: 20200106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Petrovic Shacey
CENTRAL INDEX KEY: 0001631895
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33462
FILM NUMBER: 20510881
MAIL ADDRESS:
STREET 1: 600 TECHNOLOGY PARK DRIVE
STREET 2: SUITE 200
CITY: BILLERICA
STATE: MA
ZIP: 01821
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: INSULET CORP
CENTRAL INDEX KEY: 0001145197
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 043523891
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 NAGOG PARK
CITY: ACTON
STATE: MA
ZIP: 01720
BUSINESS PHONE: 978-600-7000
MAIL ADDRESS:
STREET 1: 100 NAGOG PARK
CITY: ACTON
STATE: MA
ZIP: 01720
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2020-01-02
0001145197
INSULET CORP
PODD
0001631895
Petrovic Shacey
C/O INSULET CORPORATION
100 NAGOG PARK
ACTON
MA
01720
1
1
President and CEO
Common Stock
2020-01-02
4
F
0
1008
169.77
D
95530
D
Common Stock
2020-01-02
4
M
0
12500
30.58
A
108030
D
Common Stock
2020-01-02
4
S
0
12500
169.6298
D
95530
D
Employee Stock Option (Right to Buy)
30.58
2020-01-02
4
M
0
12500
0
D
2025-02-09
Common Stock
12500
67436
D
This transaction represents the withholding of shares upon the vesting of restricted stock units to cover the associated tax obligations.
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2019.
The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $167.20 to $173.00. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.
/s/ John W. Kapples, attorney-in-fact
2020-01-06